Yale University

EliScholar – A Digital Platform for Scholarly Publishing at Yale
Yale Medicine Thesis Digital Library

School of Medicine

1995

Autoantibodies in systemic lupus erythematosus
Ingrid Helena Olhoffer
Yale University

Follow this and additional works at: http://elischolar.library.yale.edu/ymtdl
Recommended Citation
Olhoffer, Ingrid Helena, "Autoantibodies in systemic lupus erythematosus" (1995). Yale Medicine Thesis Digital Library. 3005.
http://elischolar.library.yale.edu/ymtdl/3005

This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A Digital Platform for Scholarly
Publishing at Yale. It has been accepted for inclusion in Yale Medicine Thesis Digital Library by an authorized administrator of EliScholar – A Digital
Platform for Scholarly Publishing at Yale. For more information, please contact elischolar@yale.edu.

YALE MEDICAL LIBRARY

3 9002 08676 1054

AU1 OAN'l ll-DDIi

YSTliMie- I'.UPUS fRyTHfiyiATQSl}#

n/jvjd .Helena: Ollioffer

livers:'y

YALE
UNIVERSITY

CUSHING/WHITNEY
MEDICAL LIBRARY

Permission to photocopy or microfilm processing
of this thesis for the purpose of individual
scholarly consultation or reference is hereby
granted by the author. This permission is not to be
interpreted as affecting publication of this work or
otherwise placing it in the public domain, and the
author reserves all rights of ownership guaranteed
under common law protection of unpublished
manuscripts.

Date

Digitized by the Internet Archive
in 2017 with funding from
The National Endowment for the Humanities and the Arcadia Fund

https://archive.org/details/autoantibodiesinOOolho

AUTOANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSUS

A Thesis Submitted to the Yale University School of Medicine in Partial
Fulfillment of the Requirements for the Degree of Doctor of Medicine

Ingrid Helena Olhoffer

1

Mod L \L

YALE MEDICAL LIBRARY
OCT 1 2 1995

( A n ci

ACKNOWLEDGEMENTS
First, I would like to thank Dr. Joseph Craft for giving me the
opportunity to pursue this project and for being a great role model to which
I will always aspire.

I would also like to thank Sam Peng and Marylou

Breitenstein for teaching me the laboratory techniques required for this
project, Dr. Michele Solimena for carefully reviewing my thesis, Dr. James
Jekel for a thoughtful discussion on biostatistics, Dr. Robert McClean for
generously letting me use his completed chart review summary sheets, and
my friend Stanford Peng for a critical review of the rough draft.

Finally, I

would like to thank everyone involved for their support and encouragement
during

this

endeavor.

TABLE OF CONTENTS

Page

ABSTRACT

i

ABBREVIATIONS

iii

INTRODUCTION
History Of Autoantibodies In SLE
Characteristics Of Autoantigens
Detection Of Autoantibodies
Prevalence Of Autoantibodies
Autoantibodies As Markers Of Disease
Autoantibodies As Monitors Of Disease Activity
Role Of Autoantibodies In The Pathogenesis Of Disease
Correlation Of Autoantibodies With Clinical Manifestations
Autoantibody Sets
Etiology Of SLE

1
2
3
7
10
11
12
13
14
18
19

METHODS

30

RESULTS
The Study Population
Clinical Aspects
Autoantibodies

34
34
34
36

DISCUSSION

54

REFERENCES

61

FIGURES

Page

1. 35S Immunoprecipitation Of Positive Control Sera

48

2. 35S Immunoprecipitation of Ribosomal Protein Control Sera

49

3. Sample 35S Immunoprecipitation Of Study Population

50

4. Distribution Of The Number Of Antibodies Per Patient

51

5. Distribution Of The Number Of Antibody Sets Per Patient

52

6. Number Of Autoantibody Sets By Duration Of Disease

53

TABLES
1.

Common Antigens In Systemic Lupus Erythematosus

28

2. Clinical Correlations Found In The Literature

29

3. Characteristics Of The Study Group

39

4.

40

Initial Clinical Factors

5. Clinical Profile Of SLE Patient Population

41

6. Inter-autoantibody Associations

43

7. Autoantibody Profiles (Part I)

44

8. Autoantibody Profiles (Part II)

45

9. Autoantibodies Or Autoantibody Sets/ Patient

45

10. Autoantibody Profiles In The Literature

46

1

ABSTRACT
AUTOANTIBODY PROFILES IN SYSTEMIC LUPUS ERYTHEMATOSUS
SUPPORT A GLOBAL DEFECT IN IMMUNE TOLERANCE.
Olhoffer and Joseph Craft.

Ingrid H.

Section of Rheumatology, Department of

Internal Medicine, Yale University, School of Medicine, New Haven, CT.

Systemic lupus erythematosus (SLE) is manifested by a diversity of both
clinical manifestations and autoantibody specificities.

Previous studies

have suggested that autoantibody specificities in SLE occur in pairs (dsDNA
and histone, Ro and La, Sm and U1 ribonucleoprotein).

This led to the

hypothesis that the autoimmune response in lupus targets particles - the
nucleosome, the Ro/La ribonucleoprotein particle, and/or the spliceosome.
Given this theory, we studied the frequency of autoantibody sets and the
average number of autoantibody sets per SLE patient in regard to the
etiology of lupus.

Sera of sixty-eight patients fulfilling the American

Rheumatology Association 1982 Revised Criteria for SLE were studied for
autoantibody sets by 35S immunoprecipitation and ELISA analysis, and
autoantibody profiles previously reported in the literature were examined
for the prevalence of autoantibody sets and the average number of
autoantibody sets per patient.

Clinical/autoantibody associations, in this

previously unreported population, were determined using Chi-square
analysis with Yates' correction. The prevalences of autoantibody sets of the
following specificities were as follows: dsDNA and/or histone (59%), Sm
and/or U1 RNP (40%), and Ro and/or La (41%).

The current study and

twelve identified studies in the literature showed an average of two or
greater autoantibody sets per patient supporting lupus etiologic theories
consistent with a global defect in immune tolerance.

The following

11

associations, which are consistent with the literature, were found - antidsDNA antibodies correlated with renal pathology; anti-dsDNA and anti¬
histone antibodies correlated with hypocomplementemia; and anti-La
antibodies correlated with Rheumatoid Factor.

ABBREVIATIONS

ANA

Antinuclear antibody

ARA

American Rheumatology Association

BSA

Bovine serum albumin

CIE

Counterimmunoelectrophoresis

DNA

Deoxyribonucleic acid

ds

Double-stranded

EDTA

Ethylenediamine-tetraacetic acid

ELISA

Enzyme-linked immunosorbent assay

HLA

Human lymphocyte antigen

IL

Interleukin

IPP

Immunoprecipitation

kD

Kilodalton

lpr

Lymphoproliferation

MCTD

Mixed connective tissue disease

MHC

Major histocompatibility complex

MRL

Murphy's recombinant large

mRNA

Messenger ribonucleic acid

MW

Molecular weight

nRNP

Nuclear ribonucleoprotein

NZB

New Zealand Black

NZW

New Zealand White

PBCA

Polyclonal B cell activation

PCNA

Proliferating cell nuclear antigen

PTCA

Polyclonal T cell activation

RF

Rheumatoid factor

RNA

Ribonucleic acid

RNP

Ribonucleoprotein

rRNA

Ribosomal ribonucleic acid

SCLE

Subacute cutaneous lupus erythematosus

scRNP

Small cytoplasmic ribonucleoprotein

SD

Standard difference

SDS

Sodium dodecyl sulfate

SLE

Systemic lupus erythematosus

Sm

Smith

snRNP

Small nuclear ribonucleoprotein

ss

Single-stranded

SS

Sjogren's syndrome

Th

Helper T cell

tRNA

Transfer ribonucleic acid
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INTRODUCTION

Systemic lupus erythematosus (SLE) is manifested by a diversity of
both clinical manifestations and autoantibody specificities.

Clinical

manifestations include: dermatologic disease, serositis, musculoskeletal
disease,

neurological

disease,

vascular

disease,

renal

pathology,

hematologic disease, and constitutional symptoms (Tan et al., 1982).
Autoantibodies in SLE can be artificially divided into organ specific versus
organ non-specific antibodies (Tan 1993). The organ specific antibodies are
directed against antigens present in only a subset of cells, for example, the
hematopoietic cellular elements (red cells, white cells, and platelets) (Tan
1993); whereas organ non-specific antibodies (the focus of this project) are
directed against subcellular nuclear and cytoplasmic antigens common to
virtually every cell type, including double-stranded (ds) DNA, histones, Sm,
U1 ribonucleoprotein (RNP), Ro, La, ribosomal proteins, proliferating cell
nuclear

antigen

(PCNA),

Ku,

and

Ki

(Boey

et

al.,

1988).

These

autoantibodies have been used as markers to confirm diagnosis, shown to
play a direct role in the pathogenesis of disease, correlated with clinical
manifestations,

used

as

tools

for

the

structural

analysis

autoantigens, and examined for clues to the etiology of lupus.

of the
Possible

etiologies include: modification of self determinants, molecular mimicry,
polyclonal B cell activation (PBCA), polyclonal T cell activation (PTCA),
disclosure of "privileged sites," disclosure of "cryptic self," activation of
ignorant autoreactive cells, a deficit in T and/or B cell tolerance, or an
immunoregulatory disturbance (Theofilopoulos 1995).

The present study

takes a novel approach to examining autoantibody profiles for clues to the
etiology of SLE. In order to address this question, the following introduction
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will briefly detail the history of the autoantibodies, the molecular biology of
the autoantigens, the methods for detection of autoantibodies, the clinical
associations of the autoantibodies, and the various theories regarding the
genesis of autoantibodies.

History of Autoantibodies in SLE

Serological markers of the connective tissue diseases have an
extended history of being studied.

In 1948, Hargraves, one of the pioneers

in laboratory rheumatology, described the phenomenon of the LE (lupus
erythematosus) cell in bone marrow and associated it with SLE (Hargraves
et al., 1948). Shortly thereafter, Kunkel and colleagues showed that the LE
phenomenon was secondary to circulating antibodies against DNA, cell
nuclei

and

deoxyribonucleoprotein

polymorphonuclear

leukocytes),

(which
giving

direct
new

phagocytosis

insight

into

by
the

immunopathogenesis of SLE and shaping the development of modern
concepts of autoimmunity (reviewed in Tan 1989; and Christian and Elkon,
1986).
Since these early studies led the way for other investigators, many
other autoantibodies have been identified. In 1959, antibodies to DNA were
first reported (reviewed in Tan 1993). In 1961, Kunkel et al. described anti¬
histone antibodies (reviewed in Christian and Elkon, 1986). Discovery of the
small nuclear ribonucleoprotein (snRNP) particles began in the early 1960s
with anti-Sm being first described in SLE patients in 1966 by Tan and
Kunkel and nRNP (now called U1 RNP) being described in 1971 (reviewed in
Hardin 1989, and Mattioli and Reichlin, 1971).

Antibodies to ribosomes

were first described in 1963 (reviewed in Bonfa and Elkon, 1986).

Anti-Ro
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and anti-La antibodies were first reported to occur in patients with SLE in
1968 (reviewed in Reichlin,

1985), and in

1979, an interlaboratory

collaboration showed these antigens to be equal to the SS-A and SS-B
antigens, respectively (SS-A and SS-B were originally described in Sjogren's
syndrome) (Alspaugh and Maddison, 1979). An “autoantibody to a nuclear
antigen in proliferating cells” (PCNA) was first reported in 1978 (Miyachi et
al., 1978).
Discoveries continued into the 1980s. Anti-Ku antibodies, which were
first isolated in patients with polymyositis-scleroderma overlap syndrome,
were isolated in SLE patients in 1981 (reviewed in Reeves 1985).

Also in

1981, Tono et al. found that SLE patients have antibodies which target the Ki
antigen (reviewed in Sakamoto et al., 1989). The SL antigen, first reported
by Harmon et al. in 1981, has since been shown to be equivalent to Ki
(Bernstein et al., 1986; Sakamoto et al., 1989).
Also of historical importance, many autoantibody specificities were
discovered using patient sera and were therefore originally named after the
patient in whom they were first described (Christian and Elkon, 1986). For
example, anti-Sm and anti-Ku antibodies were first described in the sera of
patients Smith and Ku (Craft and Hardin, 1992; Christian and Elkon, 1986).

Characteristics of Autoantigens in SLE

Using patient autoantibodies as probes together with recent advances
in molecular biology, investigators have accumulated a considerable
amount of knowledge regarding the molecular identity and biological
functions of the autoantigens targeted in lupus (Table 1).
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DNA

Many patients with SLE have sera specific for their genetic

material,

deoxyribonucleic

acid

(DNA).

DNA

is

a

polymer

of

deoxyribonucleotides whose function can be described as "the storehouse of
information specifying all facets of the cell's existence (Geis 1983)".

Much

research has described the antigenic determinants recognized by anti-DNA
antibodies. Antibodies to dsDNA react with antigenic determinants present
on both double and single-stranded (ss) DNA (mainly the deoxyribose
phosphate backbone) (reviewed in Tan 1993), whereas, antibodies to ssDNA
target the purine and pyrimidine bases exposed in ssDNA (reviewed in Tan
1989 and Tan 1993).

Histones
the

Histones are a highly conserved family of basic proteins within

nucleus

which

together

with

DNA

make

up

nucleosomes.

Nucleosomes are highly structured units consisting of H2A-H2B dimers
and H3-H4 tetramers forming a core structure around which helices of
dsDNA are wound (reviewed in Tan 1989).

HI proteins mediate a higher

order of packing (reviewed in Craft and Hardin,

1992).

In SLE,

autoantibodies to histones are targeted at all the classes of histones, HI,
H2A, H2B, H3, H4, as well as the H2A/H2B and H3/H4 complexes (reviewed
in Tan 1989 and Tan 1993).

snRNP Antigens

In 1979, Lerner and Steitz first elucidated the structure

and function of these antigens which are classified as small nuclear
ribonucleoprotein (snRNP) particles - Ul, U2, and U4-U6.

Structurally,

each spliceosome snRNP particle consists of the corresponding U (uridine
rich) small RNA (Ul, U2, U4, U5, or U6), distinct from tRNA, mRNA and
rRNA,

and associated polypeptides.

The Sm protein complex consists of
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six polypeptides B (28 kD), B’ (29 kD), D (16 kD), and E-G (13-11 kD) which
are common to the Ul, U2, and U4-U6 snRNPs; whereas, the 70K (70 kD),
A (33 kD), and C (22 kD) polypeptides are uniquely associated with the Ul
snRNP. (reviewed in Tan 1989; and Craft et al., 1988; and Hardin 1986)
Functionally, snRNP particles are involved in splicing pre-mRNA as
a part of the spliceosome machinery located in the nucleus. The proteins of
these particles have most commonly been shown to be the immune target;
however, antibodies to the RNA component have also been identified
(Wilusz and Keene, 1986). Specifically, anti-Ul RNP antibodies bind 70K, A,
and/or C; anti-Sm antibodies bind B, B', D and/or E recognizing one or more
epitopes (they may also bind F and/or G) (reviewed in Tan 1989); and antiU2 RNP antibodies bind A’ and B” (Craft et al., 1988). E, F and G are rarely
autoimmune targets (reviewed in Tan 1989, and Hardin 1989).
Other important aspects of the snRNP binding specificities have been
elucidated.

For example, there is a shared conformational epitope on BVB

and D recognized by a monoclonal antibody called Y12. Furthermore, it has
been noted that several epitopes are common to the various peptides and
they have therefore been suggested as “pivotal” in the SLE autoimmune
response, (reviewed in Hardin 1989)

Ro

Anti-Ro/SS-A positive sera bind ribonucleoprotein particles.

Each

particle consists of probably two Ro proteins (52 kD and 60 kD) and 4-5 small
RNAs called Y RNAs (reviewed in Tan 1989; and Craft and Hardin, 1992).
The Ro RNAs are transcribed by RNA polymerase III.

Initially thought to

be cytoplasmic, Ro antigen is now believed to be nuclear in origin (Clark et
al., 1969). The function of Ro is unknown.
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La

La/SS-B is a conserved phosphoprotein of 46 to 48 kD. Gottlieb and Steitz

in 1989, suggested that La is a RNA polymerase III termination factor
(Gottlieb and Steitz, 1989).

Interestingly, anti-La antibodies have been

shown to target an antigen present on both the Ro and La particles,
(reviewed in Tan 1989)

Ribosomal P Proteins

Antibodies to ribosomal ribonucleoprotein (rRNP)

are directed against three proteins, PO, PI, and P2 (of 38 kD, 16 kD, and 15
kD, respectively) of the 60S ribosomal subunit (Elkon et al., 1988). As a part
of the translation machinery, these proteins are at least indirectly involved
in mRNA translation and protein synthesis.

Accordingly, on ANA

immunofluorescence, staining for these proteins is seen in both the
nucleolus and cytoplasm (reviewed in Craft and Hardin, 1992).

Ku

Ku, also called p70/p8Q, is represented by a doublet of proteins of 60-66

kD and 81-86 kD (reviewed in Tan 1989; Sakamoto et al., 1989).

At least

three epitopes (one common to both proteins) have been identified
(Francoeur et al 1986). Ku is the regulatory component of a DNA-dependent
protein kinase (Dvir et al., 1992, Gottlieb and Jackson, 1993).

Ki

Ki is a nuclear protein of 32 kD whose function is unknown (Sakamoto

et al., 1989).

PCNA

As a 36 kD cell cycle-regulated proliferation-associated protein,

PCNA is used as a probe for identifying proliferating cells and has been
reported to be the auxiliary protein of DNA polymerase-delta (Miyachi et al.,
1978; reviewed in Craft and Hardin, 1992; Swaak et al., 1990).
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Detection of Autoantibodies

Many techniques have been used to study the serology of SLE
including:

tissue

section

immunofluorescence,

cell

substrate

immunofluorescence, Farr radioimmunoassay, Crithidia immunoassay,
immunodiffusion,
blotting,

and

counterimmunoelectrophoresis,

immunoprecipitation.

Throughout

ELISA,
the

western

years,

many

seemingly conflicting studies of SLE autoantibodies have used different
assays.

Accordingly, much of the discordant data in the literature may be

explained by differences in assay sensitivities and specificities.

ANA Immunofluorescence

Antinuclear antibody immunofluorescence is

the most prevalent screening assay for the detection and quantification of
ANAs.

Tissue

section

immunofluorescence

and

cell

substrate

immunofluorescence are sensitive, nonspecific screens for autoantibodies
which are usually followed by more specific antibody tests (Christian and
Elkon, 1986).

Anti-dsDNA Detection

The common techniques for anti-dsDNA detection

include the Farr radioimmunoassay, the Crithidia immunofluorescence
assay, and the ELISA (Christian and Elkon, 1986).

The Farr assay,

described in 1968, is based on separating free DNA from DNA-antibody
complexes using saturated ammonium sulfate solutions (Wold et al., 1968).
The Crithidia assay uses a stage double-stranded solid phase form of DNA
for semiautomated immunofluorescent intensity quantification (Christian
and Elkon, 1986).

ELISAs (enzyme-linked immunosorbent assays) involve
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using purified antigen as bound substrate which is then probed with
unknown sera, with bound antibodies being detected with labeled anti-IgG
antibodies.

Studies comparing various assays have found varying

sensitivities and specificities (reviewed in Craft and Hardin, 1992).

In a

study by Swaak et al., sensitivities and specificities varied depending on the
clinical manifestations of the SLE patient population. In particular, Swaak
et al. showed qualitative and quantitative differences between patients with
CNS lupus manifestations and nephritis (Swaak et al., 1990).

Immunodiffusion

Sm, U1 RNP, Ro and La antisera were originally

detected by immunodiffusion analysis, according to Ouchterlony.

In this

assay, the presence of autoantibodies results in the formation of a visible
precipitin line between antigen of various mammalian tissue extracts and
specific antibody (reviewed in Craft and Hardin, 1992; and Tan 1991). This
technique, which has also been used to detect anti-PCNA (Boey et al., 1988)
and anti-Ku antibodies, is dependent on antigen solubility (detecting only
precipitating

antibodies),

antigen

abundance,

and

(reviewed in Christian and Elkon, 1986; and Tan 1991).

protein

half-life

Specifically,

Sm,

U1 RNP, and La tend to be highly abundant and soluble in most
mammalian tissue,

whereas Ro is present in lower concentrations in

species such as rats or mice (reviewed in Christian and Elkon, 1986).
Because the Ro antigen varies in concentration in cells from one animal
species to the next, many traditionally “ANA-negative” lupus patients have
anti-Ro (reviewed in Christian and Elkon, 1986). A newer technique related
to immunodiffusion is counterimmunoelectrophoresis (CIE) (reviewed in
Christian and Elkon, 1986).
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ELISA

Described above, ELISAs are currently used both in research and

clinically to screen for specific autoantigens.

Numerous studies have been

done comparing various detection assays with ELISAs.

Maddison et al.

showed that ELISA has a greater sensitivity but lower specificity in
comparison with immunodiffusion for nRNP, Sm, Ro and La (Maddison et
al., 1985). Anti-histone antibodies are usually detected with ELISA because
histones are insoluble at physiologic ionic strength and pH. (reviewed in
Christian and Elkon, 1986)

lmmunoprecipitation (IPP)
technique.)

(See methods section for description of

Currently one of the most sensitive and specific methods for

characterizing the targets of autoantibodies is immunoprecipitation
(reviewed in Craft and Hardin, 1992; and Christian and Elkon, 1986).
Kessler was one of the first to use the technique of immunoprecipitation
(reviewed in Christian and Elkon, 1986), and in 1979,

Lerner and Steitz

used this technique to immunoprecipitate radiolabeled RNA protein
complexes (Lerner and Steitz, 1981).

Immunoprecipitation to detect anti-

snRNP, anti-Ro, and anti-La antibodies is well described (Craft and
Hardin, 1992).

Immunoprecipitation has also been used to identify

antibodies to rRNP, Ki and Ku (Boey et al., 1988).

One of the important

elements of this technique is that non-antigenic proteins and RNA
associated

with

the

targeted

antigen

are

co-precipitated.

Immunoprecipitation also has utility in detecting previously unrecognized
antigens.

Western Blotting

Western blotting involves probing protein which has

been transferred to nitrocellulose paper after SDS gel separation. It is a very
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specific way of identifying protein antigens (reviewed in Christian and
Elkon, 1986). Bonfa and Elkon showed that Western blotting was the most
sensitive and specific method for the detection of anti-ribosomal P protein
antibodies

in

comparison

to

CIE

and

cytoplasmic

indirect

immunofluorescence (Bonfa and Elkon, 1986).

Prevalence of Autoantibodies in SLE

Frequencies of Individual Autoantibody Specificities

The frequency of

particular autoantibodies found in a given SLE population is assay
dependent; accordingly, many varying percentages have been reported
(Table 8). Nevertheless, some generally accepted frequencies are quoted in
the literature (Table 1). Studies have shown that approximately 40% of SLE
patients

have

anti-dsDNA

antibodies,

and

a

considerably

higher

percentage, approximately 70%, have anti-ssDNA antibodies (reviewed in
Tan 1989).

Approximately 70% of SLE patients have been shown to have

anti-histone antibodies (reviewed in Tan 1989). Anti-Sm and anti-Ul RNP
antibodies are found in approximately 15-30% and 32% of SLE patients,
respectively (Boey et al., 1988; reviewed in Tan 1989; Swaak et al., 1990).
Anti-Ro antibodies are present in approximately 35% of SLE patients and
anti-La antibodies are found in approximately 15% of patients (reviewed in
Tan 1989).

At least 10-15% of patients with SLE have antibodies reactive

with the ribosomal P proteins (Christian and Elkon, 1986; Elkon et al.,
1988). Anti-Ku antibodies occur in approximately 5-10% of SLE patient sera
(Boey et al., 1988; reviewed in Tan 1989; Sakamoto et al., 1989), and 6-21% of
SLE patients have antibodies directed against the 32 kD Ki/SL antigen (Boey
et al., 1988; Bernstein et al., 1984; Reichlin 1985; Swaak et al., 1990). Anti-
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PCNA antibodies are present in 3-21.4% of SLE patients (Boey et al., 1988;
Sakamoto et al., 1989; Swaak et al., 1990).

Autoantibodies as Markers

Autoantibody profiles are important clinically

in distinguishing SLE from many of the other autoimmune diseases, such
as, scleroderma, Sjogren's syndrome (SS), mixed connective tissue disease
(MCTD), and dermatomyositis/polymyositis.

Certain antibodies, including

anti-Sm and anti-dsDNA antibodies, have been shown to be specific
diagnostic markers for SLE , whereas others, such as anti-ssDNA and antiRo antibodies, are only minimally helpful in narrowing the differential
diagnosis.
Anti-Sm antibodies are generally considered pathognomonic for SLE
(Notman et al.,

1975) and are part of the American Rheumatology

Association (ARA) 1982 revised criteria (Tan et al., 1982).

Furthermore, a

high titer of antibodies to dsDNA is considered a marker for SLE and is
rarely present in other diseases (reviewed in Tan 1993; and Craft and
Hardin, 1992).

Whereas the sensitivity of anti-Sm antibodies is only

approximately 30% for SLE, the majority of patients with active lupus have
anti-dsDNA reactivity with moderate to high titers (Christian and Elkon,
1986).

Anti-P antibodies have also been reported as fairly specific to SLE.

Bonfa and Elkon found anti-P antibodies in 17 out of 20 (85%) SLE patients
versus 0 out of 34 non-SLE patients (Bonfa and Elkon, 1986).
The other major antibody specificities of SLE are not commonly
reported as being as specific for SLE. For example, anti-Ul RNP antibodies
are also found in (and actually necessary for a diagnosis of) MCTD
(reviewed in Tan 1989; and Craft and Hardin, 1992; and Craft et al., 1988)
and, rarely, in rheumatoid arthritis, Sjogren's syndrome, scleroderma,
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and polymyositis (reviewed in Craft and Hardin, 1992).

Anti-U2 RNP

antibodies have been described in patients with MCTD,

psoriasis,

scleroderma-polymyositis overlap syndrome, other overlap syndromes often
including myositis, and patients without an identified disease (reviewed in
Craft et al., 1988). Anti-histone antibodies are found additionally in juvenile
rheumatoid

arthritis,

rheumatoid

arthritis,

and

in

high

titer

are

characteristic of patients with drug-induced lupus (reviewed in Craft and
Hardin, 1992).

Anti-ssDNA is present in patients with other rheumatic

diseases and in patients with nonrheumatic diseases, most commonly
chronic infection (reviewed in Tan 1993).
In addition to SLE, anti-Ro and anti-La autoantibodies are found in
the majority (approximately 70% and 45-60%, respectively) of patients with
Sjogren's syndrome (reviewed in Tan 1993; Maddison et al., 1985).

Ro and

La specificities are also associated with polymyositis, scleroderma and
rheumatoid arthritis (reviewed in Craft and Hardin, 1992).

Anti-La

antibodies are also detected in patients with primary biliary cirrhosis and
patients without a clinical diagnosis (reviewed in Craft and Hardin, 1992).
Anti-Ku antibodies are seen in patients with scleroderma and MCTD
(Reeves 1985), and anti-Ki antibodies are found in patients with MCTD,
primary Sjogren's syndrome, and rheumatoid arthritis, in addition to SLE
(Sakamoto et al., 1989).
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Autoantibodies as Monitors of Disease Activity

Autoantibodies have also been used to monitor disease activity. It has
most clearly been shown that the titer of anti-dsDNA antibodies can
correlate with SLE disease activity.

Swaak, Tan, and others have noted a

decrease in anti-dsDNA antibodies that correlates with clinical disease
exacerbations, compatible with immune-complex formation (reviewed in
Christian and Elkon, 1986). Other patients with active SLE have been noted
to have titers magnitudes higher than normal controls and patients with
inactive SLE (reviewed in Christian and Elkon, 1986). In a study of patients
with connective tissue diseases, Houtman et al. correlated anti-nRNP/Sm
levels with disease activity (Houtman et al., 1985). Boey and Tan studied 94
SLE patients and found that patients with anti-Sm antibodies were more
likely to have active lupus (Boey et al., 1988).

Scopelitis et al., in a small

study, suggested that anti-Ro titers also correlate with disease activity
(Scopelitis et al., 1980).

Given that autoantibody titers fluctuate, some

studies of SLE autoantibody profiles have used disease activity as a selection
criterion including only those sera of patients with a disease exacerbation
(Swaak et al., 1990).

Role of Autoantibodies in the Pathogenesis of Disease

In addition to their role as markers of disease and disease activity,
autoantibodies in SLE have been shown to play a direct role in tissue
damage. There is compelling evidence that dsDNA-antibody complexes are
involved in the pathogenesis of renal disease in many SLE patients by
mediating immune complex injury (Maddison et al., 1985) and can be a risk
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factor for nephritis (reviewed in Craft and Hardin, 1992). Glomerular
eluants have been shown to have more than thousand-fold concentrations of
anti-dsDNA relative to the sera of the same patient (Christian and Elkon,
1986).

Additionally, ssDNA is present in immune complexes in the

glomeruli of patients with SLE (Maddison et al., 1985). Further studies have
shown that the ability of anti-dsDNA antibodies to fix complement
determines the pathogenicity (reviewed in Craft and Hardin, 1992).
Evidence exists that implies that anti-Ro antibodies may be directly
involved in the pathogenesis of neonatal SLE, correlating with both an
increased risk of neonatal skin rash and congenital complete heart block
(Maddison et al., 1985).

Interestingly, neonatal lupus is characterized by

anti-Ro and anti-La antibodies in both the mother and the child, with the
neonatal skin lesions disappearing together with the antibodies which were
transferred transplacentally (Reichlin, 1985).

Anti-Ro antibodies cause

neonatal heart block by directly affecting the conduction system (Buyon
1992).

In patients with subacute cutaneous lupus erythematosus (SCLE),

studies have suggested that anti-Ro antibodies may bind to the Ro antigen
on keratinocytes, contributing to the skin pathology characteristic of this
disease (reviewed in Craft and Hardin, 1992).

Human keratinocytes bind

anti-Ro and anti-La antibodies if cultured in the presence of estradiol, and
UV light has

been

shown

to

induce

anti-Ro

antibody

binding to

keratinocytes (reviewed in Tsokos 1992).

Correlation of Autoantibodies with Clinical Manifestations

In addition to these studies showing a direct pathologic role for
antibodies, many past studies have examined the clinical significance of
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autoantibody profiles in SLE patients by searching for associations between
autoantibodies and clinical manifestations.

Many investigators have

studied a single antibody and tried to relate it to special clinical features.
Others have realized that a particular autoantibody specificity does not
stand alone and have tried relating antibody patterns to clinical features.
Furthermore, certain antibodies and/or antibody combinations have often
been proposed to be markers for particular subsets of patients. Associations
previously reported in the literature are discussed below and shown in
Table 2.

Unfortunately, many reported associations do not duplicate when

tested by other investigators on different populations and/or with different
assays.

dsDNA

One of the most widely recognized associations is that of anti-

dsDNA, hypocomplementemia, and nephritis (reviewed in Tan 1989; and
Craft and Hardin, 1992; Swaak et al., 1990). Swaak and colleagues looked at
autoantibody profiles in a group of SLE patients in the Netherlands and
found that in addition to anti-dsDNA antibodies correlating positively with
nephritis, they correlate negatively with CNS manifestations (Swaak et al.,
1990); and Thompson et al., in 1993, found an association between antidsDNA antibodies and hematologic disease and/or a malar rash (however
these are not widely observed associations).

Histone

In SLE patients, one study associated anti-histone antibodies with

photosensitivity (reviewed in Tan 1989; and Swaak et al., 1990). More widely
accepted, anti-histone antibodies, in the absence of anti-dsDNA, anti-Sm
and other autoantibodies, are characteristic of drug-induced lupus.
Interestingly, the pattern of anti-histone specificity varies depending if they
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are drug-induced and if so, which drug caused the antibody response
(Christian and Elkon, 1986).

For example, procainamide-induced anti¬

histone antibodies are targeted to the H2A/H2B complex, whereas,
hydralazine-induced anti-histone antibodies are IgM antibodies targeted
against histones H3 and H2A (Christian and Elkon, 1986).

Ro and/or La

Maddison and Reichlin, and others, have associated anti-Ro

antibodies with severe photosensitive dermatitis.

(As mentioned above,

anti-Ro antibodies are believed to have a direct pathological affect on
keratinocytes.) Some of these dermatitis patients have been classified into a
subset of lupus designated subacute cutaneous lupus erythematosus
(SCLE). Patients with subacute cutaneous lupus are highly photosensitive
and

have

prominent

skin

lesions,

characterized

as

a

nonscarring

dermatitis, in the setting of less other organ involvement, (reviewed in
Maddison et al., 1985)
Maddison and Reichlin associated anti-Ro positive, anti-La negative,
sera with lupus nephritis (Maddison et al., 1985).

However, in this

particular study 77% of patients positive only for anti-Ro antibodies also had
anti-dsDNA antibodies which, as stated above, are generally agreed to be
involved in the pathogenesis of renal disease in lupus (Maddison et al.,
1985). In a retrospective study of SLE patients by Maddison et al. (reviewed
in Reichlin 1985), anti-Ro antibodies were also associated with an increased
frequency of rheumatoid factor positivity (Bell and Maddison, 1980) and
coexistent Sjogren's syndrome or keratoconjunctivitis sicca (Reichlin 1985).
Anti-Ro antibodies have also been associated with vasculitis (Reichlin 1985),
hepatitis (reviewed in Craft and Hardin, 1992), decreased frequency of
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Raynaud’s (Bell and Maddison, 1980) and non-thrombocytopenic purpura
(Reichlin 1985); however, these associations have not been confirmed.
Hamilton et al. studied antibodies to Ro, La, and Sm/nRNP in a
group of SLE patients and identified two Ro autoantibody subgroups,
associating the anti-Ro only group with HLA alleles DR2 and DQwl, and
the anti-Ro and La subgroup with HLA alleles D8, DR3, DRw52, DQw2,
older age at disease onset, sicca complex and less renal pathology
(Hamilton et al., 1988).

Anti-La antibodies are often associated with the

sicca syndrome (reviewed in Craft and Hardin, 1992).

Sm

Anti-Sm antibodies are found in a higher frequency in blacks than

whites (Arnett et al., 1988; Ward and Studenski, 1990) and have been
associated with decreased frequency of CNS disease manifestations and
nephritis (Swaak et al., 1990) (although this may be assay-dependent;
reviewed in Craft and Hardin, 1992) and, in one study, an increased
frequency of malar rash and hematologic pathology (Thompson et al., 1993).

U1 snRNP

Anti-Ul antibodies have also been associated with black race

(Arnett et al., 1988). A study by Bell and Maddison looked at 64 patients and
associated anti-Ul RNP with a lower frequency of serositis, renal disease,
and Raynaud’s phenomenon (Bell and Maddison, 1980).

Swaak et al.,

however, looking at a Netherlands' population found anti-Ul

RNP

correlated with an increased frequency of pleuropericarditis and CNS
manifestations (Swaak et al., 1990); and Thompson et al., in 1993, found an
association with increased frequency of Raynaud’s.

Williamson et al

correlated vasculitis with the presence of anti-Ul RNP (Williamson et al.,
1983). These correlations have yet to be widely confirmed.
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Ribosomal Proteins

Bonfa and Elkon, in 1986, associated anti-ribosome P

antibodies with lupus psychosis using Western blotting technique. In 1990,
Swaak suggested that these antibodies are also associated with sicca
syndrome.

Ki

Tojo et al. suggested an association between anti-Ki antibodies and

arthritis, pericarditis, fever, and pulmonary hypertension.

Furthermore,

an association between anti-Ki antibodies and a higher prevalence of CNS
involvement has been suggested (Bernstein et al., 1984; Sakamoto et al.,
1989; reviewed in Swaak et al., 1990).

PCNA

Anti-PCNA antibodies have not been associated with any particular

clinical symptoms (reviewed in Craft and Hardin, 1992).

Autoantibody Sets

The mutual occurrence of specific antibodies in sets has been evident
to investigators since the first autoantibodies were reported.

In 1973,

Mattioli and Reichlin wrote a paper entitled “Physical Association of Two
Nuclear Antigens

and Mutual Occurrence of their Antibodies:

the

Relationship of the Sm and RNA Protein (Mo) Systems in SLE Sera”
which

they

discuss

autoantibodies.

the

mutual

always

antibodies

of Sm

and

U1

RNP

Since then, the occurrence of common autoantibodies in

sets has been repeatedly confirmed.
almost

occurrence

in

In addition to anti-Sm antibodies

accompanying anti-Ul

often

accompany

RNP antibodies,

anti-histone

antibodies,

anti-dsDNA
and

anti-La
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antibodies/SS-B antibodies are almost always associated with anti-Ro
antibodies (reviewed in Hardin 1986). Other sets identified include that
antibodies to histones HI and H2B are almost always found together
(reviewed in Hardin 1986) and that anti-U2 RNP antibodies are associated
with anti-Ul RNP antibodies (Craft et al., 1988). Furthermore, these
antibodies tend to occur in an ordered sequence (i.e., U1 RNP occurs before
Sm and Ro before La) (reviewed in Hardin 1986).
These sets are characterized by targeting particles that are a part of
the same macromolecular structure, and as discussed by Hardin in 1986,
“the most prominently recognized autoantigens reside on 3 types of
nucleoprotein particles: the nucleosome, the U1 snRNP and the Ro scRNP
[small cytoplasmic ribonucleoprotein] [sic].” These observations led Hardin
and Tan to hypothesize independently that the immune response in SLE
targets macromolecular particles (Hardin 1986, reviewed in Theofilopoulos
1995).

Etiology of SLE

The

etiology of the

autoimmune

erythematosus remains unclear.

response in

systemic

lupus

Epidemiological studies have suggested

that susceptibility to lupus is multifactorial with investigations suggesting
genetic, hormonal and environmental components to SLE (reviewed in
Sinha et ah, 1990). Evidence supporting a genetic component includes that
lupus is associated with the major histocompatibility complex (MHC)
molecules HLA-B8, DR2, DR3, and DQwl (Maddison et al.,

1985).

(However, monozygotic twin pair studies show a concordance less than
100% indicating that MHC genes are not the sole factor in determining
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lupus) (reviewed in Sinha et al., 1990).

A 9:1 female to male ratio in

patients with SLE is well documented and strongly suggests a hormonal
component to SLE.

Other evidence for the role of sex hormones includes

that testosterone enhances suppressor cell activity; estrogens have a
stimulatory effect on B cells and a suppressive effect on regulatory cell
activity; and lymphocytes respond with increased activity to pokeweed
mitogen in the presence of estradiol and with decreased activity in the
presence of testosterone (reviewed in Tsokos 1992). Current possibilities for
the genesis of SLE, which will be briefly reviewed below, include: the
particle hypothesis, the modified self hypothesis, the molecular mimicry
model, polyclonal B and/or T cell activation, the release of anatomically
sequestered antigens, the "cryptic self' hypothesis, the self-ignorance
hypothesis,

errors

in

B

and/or

T

cell

tolerance,

and

defects

in

immunoregulation (reviewed in Theofilopoulos 1995).

The Particle Hypothesis

As stated above, the autoantibodies of lupus

patients commonly occur in sets (DNA/histone, Sm/Ul RNP, and Ro/La).
These

sets

are

characterized

by

targeting

particles

of

common

macromolecular structures: the nucleosome, the spliceosome and the Ro
ribonucleoprotein. Such observations led to the hypothesis that the immune
response in SLE targets macromolecular particles (Hardin 1986).

The

particle hypothesis of autoimmunization, proposed independently by Tan
and Hardin, suggests that the total autoimmunogenic repertoire of lupus is
localized on a limited number of subcellular particles
reviewed in Theofilpoulos 1995).

(Hardin 1986,

21
Modified Self Model

In 1986, Hardin suggested that an inciting agent may

structurally alter selected macromolecules,
(Hardin 1986).
induced

lupus

making them

antigenic

In support of this modified self model, patients with drugtarget the

same histone

epitopes

as

patients

with

spontaneous lupus (Grayzel et al., 1991).

Molecular Mimicry Model

Infection has been shown to precede the onset of

lupus which, together with the genetic predisposition, supports the
molecular mimicry model.

This model suggests that an exogenous agent

bearing an epitope identical or similar to a host protein triggers an
autoantibody response that may diversify (via cognate T cell - B cell
interactions) to include autoantibodies to other epitopes on the inciting
autoantigen or to an epitope on proteins of a multiprotein particle.

Many

studies support this theory.
Lerner et al., in 1981, observed that certain Epstein-Barr encoded
RNAs (EBER) are specifically precipitated by anti-La antibodies supporting
the hypothesis that the immune response to La is triggered by binding of
host proteins bearing these antigenic determinants to products of viral
infection, the resultant complex being immunogenic (Lerner et al., 1981).
Also, Chan et al. showed similarities between La and the adenovirus 72 kD
DNA binding protein (Chan et al., 1986).
polyvalent

pneumococcal

Grayzel et al. studied the sera of

polysaccharide vaccinated

nonautoimmune

individuals showing a rise in anti-pneumococcal antibodies targeting DNA
(anti-dsDNA associated idiotype) (Grayzel et al., 1991). Elkon et al. showed
that the properties of the ribosomal protein autoantigen are similar to those
of foreign protein antigens (Elkon et al., 1988).
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Polyclonal B Cell Activation (PBCA)

These above theories alone do not

explain the observation that autoantibodies in the same patient may target
proteins from separate intracellular particles (a significant number of
patients have antibodies to cytoplasmic, cell surface and nuclear antigens)
(Grayzel et al., 1991). The great diversity of autoantibodies in SLE is quoted
as being one of the major pieces of evidence supporting polyclonal B cell
activation as a primary feature in the pathophysiology of the lupus immune
response (reviewed in Hardin 1986). Earlier models of PBCA suggested that
it was secondary to intrinsic B cell hyperactivity or suppressor T cell
deficiencies (reviewed in Hardin 1986).

Current findings which support

PBCA in SLE include: the number of B cells that secrete immunoglobulin is
increased in lupus; the number of spontaneously activated B

cells

correlates with disease activity, serum-DNA binding and low levels of
serum C3; and bone marrow from patients with SLE contains large
numbers of B cells autonomously secreting immunoglobulin (reviewed in
Tsokos 1992).

Polyclonal T Cell activation (PTCA)

On the other hand, a diversity of

autoantibodies could also be secondary to intrinsic T-helper (Th) cell
hyperactivity - PTCA. In various murine models, T cell contact is required
for B cell production of polyclonal immunoglobulins (Fatenejad et al., 1993).
Accordingly, anti-CD4 (a surface marker of Th cells) monoclonal antibodies
prevent polyclonal Ig synthesis, and autoantigen-specific T cells are
necessary for anti-dsDNA production (reviewed in Craft 1994 unpublished).
Studies on human lupus patients have yielded isolated autoantigen-specific
T cells (reviewed in Tsokos 1992). In 1993, a small clinical trial by Tokuda et
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al. suggested that cyclosporin A (CsA), an inhibitor of Th and cytotoxic cell
activation, reduces the disease activity of SLE (Tokuda 1994).

Release of Anatomically Sequestered Antigens

Interestingly, many

antigens in lupus are intracellular and are in "privileged" sites that are
normally inaccessible to circulating autoantibody.

Hardin suggested that

these intracellular particles may be protected by lower levels of tolerance
(Hardin 1989).

It is unclear how such intracellular antigens become

involved in pathogenesis; however, studies have shown that intracellular
molecules can escape autolytic degradation and be released into the
extracellular environment.

These molecules are then capable of being

targeted by preexisting circulating antibody.
anti-dsDNA

antibodies

complex with

This is seen in lupus when

DNA

and

initiate

pathology.

Furthermore, other normally intracellular antigens have been located
extracellularly. Ro and Sm have been identified on keratinocytes and Sm is
expressed on the cell surface in the kidney in some patients, (reviewed in
Tan 1991)

"Cryptic

Self'

Hypothesis

As explained in a recent review by

Theofilopoulos (1995), this theory is based on the concept that MHC
molecules usually process and present "self-determinant" proteins which
constitute the dominant self.

The immune system is normally tolerant to

these self-proteins, but there are poorly displayed cryptic determinants
which do not induce tolerance.

Cryptic epitopes, generated by aberrant

antigen processing of self or foreign polypeptides, may thus activate
autoreactive cells and promote autoantibody production.

For example,
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cytochrome C peptide has been shown to contain a "cryptic" peptide
(Mamula 1993).

Self-ignorance Hypothesis

The self-ignorance hypothesis suggests that T

cells specific for extrathymic antigens undergo anergy because of the
absence of appropriate "costimulatory" factors.

A popular model for this

theory is that a virus, such as coxsackievirus or mumps, upregulates MHC
and costimulatory factors, and contributes to (3 islet cell destruction in
diabetes mellitus (Hou et al., 1993; Gerling et al., 1991; Loria et al., 1984;
Parkkonen et al., 1992; Szopa et al., 1993; Vuorinen et al., 1992).

T and/or B Cell Tolerance Defect

This theory suggests that in the normal

host, autoreactive T and/or B cells are present but by some mechanism are
tolerant.

A defect in this mechanism could hypothetically result in a

polyclonal autoantibody response.

Various evidence has been accumulated

to support this theory. For example, SLE-prone lpr mice are defective in the
Fas apoptosis gene and have activated autoreactive T and B cells due to a
defect in peripheral programmed cell death,

(reviewed in Theofilopoulos

1995)

Immunoregulatory Disturbances

Certain T cell regulatory subsets have

been suggested to induce or inhibit disease development. Specifically,
(A)

Defects of T-suppressor lymphocyte function may be involved in

the pathogenesis of SLE. In support of this theory, the absolute number of T
lymphocytes

in

SLE

patients

is

decreased

lymphocytes are present in normal number.
patients

have

a

decrease

in

the

whereas

peripheral

B

More specifically, SLE

suppressor/cytotoxic

lymphocyte
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subpopulation, as defined by the presence of cell surface markers.
Furthermore,

Tar cells,

which

are

considered

suppressor/effector cells, are decreased in SLE.

to be

precursors

of

Low activity of natural

killer cells, which are known to suppress B cell function and kill virusinfected cells, is associated with SLE disease activity.

Also, some studies

have shown that concanavalin A-induced suppressor cell function in
patients with SLE is deficient.

Deficient suppressor cell activity has been

shown to correlate with SLE disease activity, serum DNA binding and low
serum C3 levels.

Epstein-Barr virus associated suppressor/cytotoxic cell

function in EBV seropositive SLE patients has also been shown to be
defective, supporting a secondary infectious component in addition to a
primary defect in immunoregulation. (reviewed in Tsokos 1992)
(B)

Increased T-helper activity has also been considered a possible

etiologic theory.

Evidence for this theory comes from several sources.

First, patients with active SLE have been shown to have increased
expression of DR antigens on the surface of their T cells. DR+ cells provide
help to autologous B cells to secrete immunoglobulin.
several

lupus

patients

and

some

murine

models

Furthermore, in
of lupus,

T

cell

subpopulations which provide help to B cells to secrete immunoglobulin
have been isolated. For example, the CD3+CD4'CD8‘ subpopulation in SLE
patients with active disease have been shown to provide help to autologous B
cells to secrete anti-dsDNA antibodies, whereas normal controls failed to do
so. (reviewed in Tsokos 1992)
Problems with the theory of a defect in immune regulatory cells
include that anti-T-lymphocyte antibodies have been noted in lupus and that
anti-dsDNA antibodies have been found to bind surface structures of
normal

human

T

cells.

Consequently,

the

decreased

number

of
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lymphocytes in SLE may be a result and not a cause of lupus, (reviewed in
Tsokos 1992)

The above etiologic theories can be grossly divided into two main
categories: those that support a global defect in immune tolerance versus
those that support a single immunogen-guided response.

Because a

limited number of autoantigens appear targeted in SLE, autoantibody
profiles can be examined hoping to support one main theory. A simple way
of addressing this question is to ask how many different immunogens a
single patient's serum targets. Two studies in the past have addressed the
average number of antibody specificities per patient: in 1975, Notman and
Tan found nine SLE patients had three or four individual specificities
(Notman et al., 1975).

This was confirmed by Boey and Tan in 1988 who

found an average of 2.9 antibodies per SLE patient.

The presence of more

than one autoantibody per patient could be used to support a global defect in
tolerance; however, given the hypothesis by Hardin and Tan that the
autoimmune response targets particles (e.g., the nucleosome, the Ro/La
RNP particle, the spliceosome), it may be more relevant to examine the
number of autoantibody sets, not individual specificities, per patient.
question has not been previously addressed in the literature.

This

The present

study addressed this question by immunologically studying a group of SLE
patients followed at Yale University and the surrounding New Haven area,
as well as reanalyzing the autoantibody profiles previously reported in the
literature.

The

sensitive

and

specific

methods

of

ELISA

and

immunoprecipitation were used to determine the specificities of each
patient's serum.
the

prevalence

Since this patient population was previously unstudied,
of

defined

autoantibodies

are

reported,

and
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autoantibody/clinical correlations were examined to study if associations
found in other populations could be confirmed.
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Table 1
Common antigens in systemic lupus erythematosus.

Cellular antigen

Characteristics

Frequency in SLE

Reference

dsDNA
ssDNA
Histones

Nucleic acid
Nucleic acid
HI, H2A, H2B, H3-4 proteins

40
70
30-70

Sm

mRNA processing
Ul, U2, U4-6 snRNA
B,B\ D, E proteins
mRNA processing
Ul snRNA
70 kD, A, C proteins
RNA processing
60kD, 52kD proteins
Y1-Y5 RNA
RNA polymerase III
termination complex
46kD, 48kD phosphoproteins
RNA
Protein translation
38kD, 16kD, 15kD
phosphoproteins

15-30

Tan 1989
Tan 1989
Swaak et al., 1990
Tan 1989
Swaak et al., 1990
Tan 1989

U1 RNP

Ro/SSA

La/SSB

Ribosomal P
proteins

32

Boey et al., 1988

25-35

Tan 1989
Reichlin 1985

15

Tan 1989

10-15

Bonfa and Elkon,
1986
Christian and Elkon,
1986
Elkon et al., 1988
Boey et al., 1988
Swaak et al., 1990
Sakamoto et al., 1989
Boey et al., 1988
Tan 1989
Sakamoto et al., 1989
Boey et al., 1988
Bernstein et al., 1984
Reichlin 1985
Swaak et al., 1990

PCNA/cyclin

DNA replication
36kD protein

3/7.9-21.4

Ku

86kD, 66kD nuclear protein

5-10

SL/Ki

32kD protein

6.3-21

* adapted from a review by Tan
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Table 2
Clinical correlations found in autoantibody profile studies in the literature.

Antibody

Clinical/Lab Association

References

dsDNA

Nephritis, negative CNS, malar rash,
renal, hematologic, hypocomplementemia

Thompson et al., 1993
Swaak et al., 1990

Histone

Photosensitivity, drug induced lupus

Thompson et al., 1993
Swaak et al., 1990

Ro

HLA-B8/DRw3, skin rash, RF positivity
Congenital heart block, neonatal lupus
photosensitivity, Sjogren's syndrome
subacute cutaneous lupus, hepatitis
vasculitis, thrombocytopenic purpura
HLA-DR2/DQw 1

Bell and Maddison,198(
Maddison et al., 1985
Thompson et al., 1993
Craft and Hardin, 1992
Thompson et al., 1993
Reichlin, 1985
Hamilton et al., 1988

La

CNS, rashes, photosensitivity, Sicca syndrome,
negative nephritis, HLA-D8/DR3/DRw52/DQw2

Craft and Hardin, 1992
Maddison et al., 1985
Hamilton et al., 1988
Thompson et al., 1993
Swaak et al., 1990

Sm

Negative CNS or nephritis, malar rash
renal, hematologic, hypocomplementemia

Thompson et al., 1993
Swaak et al., 1990

U1RNP

Vasculitis
CNS, pleuropericarditis
negative serositis, renal disease, and Raynaud’s
increased Raynaud’s, hematologic

Williamson et al., 1983
Swaak et al., 1990
Bell and Maddison, 198(
Thompson et al., 1993

Ki

CNS, arthritis, pericarditis, pulmonary HTN, fever Sakamoto et al., 1989,31

Ribosomal P proteins Sicca syndrome, lupus psychosis

Swaak et al., 1990
Bonfa and Elkon, 1986

Other
Ro and U1RNP”-”

Less Raynaud’s

dsDNA &/or Sm

Proteinuria, renal casts, leukopenia,
Thompson et al., 1993
lymphopenia, thrombocytopenia,
hypocomplementemia, malar rash,
increased prevalence and severity of clinical manifestations

Bell and Maddison, 198(
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PATIENTS AND METHODS

Sera. Serum samples from 68 patients with systemic lupus erythematosus were
obtained from the Division of Rheumatology, Department of Medicine, Yale University.
All patients were diagnosed with SLE based on fulfilling at least four of 11 of the American
Rheumatology Association's 1982 Revised Criteria for the Classification of SLE.
Sera from 11 lab technicians were used as normal controls.

Prototype sera

containing antibodies to Ro, La, U1 RNP , Sm, dsDNA, histones, Ku, Ki, PCNA, and
ribosomes were previously obtained by Dr. Joseph Craft. Six negative human plasma
controls and six standard human plasma controls containing antibodies to Ro, La, U1
RNP, Sm, dsDNA, and histones were obtained from Apotex Scientific, Inc.
ELISAs. Kits were obtained from Apotex Scientific, Inc., and sera were tested
as per protocol outlined by Apotex. Patient and control sera were diluted (1:500 for Ro,
La, Ul, and Sm; and 1:100 for DNA and histones) in phosphate, BSA and 0.5% sodium
azide buffer and incubated with antigen for 60 minutes. Coated wells were washed with
borate and 0.8% sodium azide buffer three times, and antigen-antibody product was
labeled with alkaline phosphatase labeled anti-human IgG murine monoclonal antibody for
30 minutes. After three washes with borate buffer, labeled antigen-antibody complexes
were developed with Mg2+/phenolphthalein monophosphate substrate for 30 minutes. The
alkaline phosphatase enzyme reaction was stopped with EDTA solution and the absorbance
was read at 550nm (Titertek Multiskan model 310 spectrometer).
Preparation of radiolabeled cell extract. HeLa cell extract was prepared as
previously described (Craft and Hardin 1992). HeLa cells were radiolabeled for 8-14
hours with 35S-methionine (5uCi/ml of cells; ICN Biomedical, Irvine, CA), collected by
centrifugation for 10 minutes at l,000g, washed in 10-12 pellet volumes of Tris-buffered
saline

(TBS;

lOmM Tris-Cl,

pH

7.4,

150mM

NaCl),

and resuspended

in

immunoprecipitation buffer (IPP; lOmM Tris-Cl, pH 8.0, 500mM NaCl, 0.1% Nonidet P-
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40). Resuspended labeled cells were sonicated 3 times each for 30 seconds with a Branson
sonifier at setting 3, centrifuged for 15 minutes at 15,000g 4° C to remove cellular debris,
and the supernatant was collected.
Immunoprecipitation of radiolabeled cell extracts.

Immunoprecipitation

of radiolabeled cell extract was performed as previously described (Craft and Hardin
1992).

Five pi patient or 1-5 pi control sera and 2 mg protein A-Sepharose CL-4B

(Pharmacia, Piscataway, NJ)

were combined in 400 ul IPP buffer by end-over-end

rotation (Labquake Shaker; Lab Industries, Berkeley, CA) for two hours at 4° C. After
three washes with IPP buffer, the antibody-coated Sepharose beads were resuspended in
400 pi IPP buffer and combined with 50-100 pi 35S labeled cell extract by end-over-end
rotation for 2 hours at 4° C. Antibody-protein complexes were washed three times with
cold IPP buffer, resuspended in 3 to 4 pellet volumes of SDS-sample buffer (2% SDS,
10% glycerol, 0.5M Tris Cl/0.4% SDS, pH 6.8, mercaptoethanol, 0.005% bromphenol
blue); and after vortexing and heating at >95° C for 5 minutes, the proteins were
fractionated on SDS polyacrylamide gels. The gels were enhanced with 0.5M sodium
salicylate, dried and analyzed by autoradiography. Results were based on comparison with
prototypic sera (Figures 1,2 and 3).
Meta-analysis.

A literature search was carried out and previously reported

autoantibody profiles of SLE patients were analyzed. The minimal average number of
autoantibody sets per patient was calculated based on the reported data. In studies assaying
for only several autoantibodies, the calculated average number of autoantibody sets per
patient may grossly underestimate the actual number of sets.
Clinical Evaluation.

Patients were evaluated by retrospective clinical chart

review (raw data collected largely by Dr. Robert McClean, Rheumatology Fellow at the
Yale University School of Medicine). All 68 patients included in the study were diagnosed
with SLE according to the ARA's 1982 Revised Criteria. Clinical information on patients
was cumulative and not necessarily obtained solely at the time sera were drawn.
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Dermatologic disease was diagnosed by the presence of malar rash,
photosensitivity, alopecia, mucous membrane ulcers, discoid rash, livedo reticularis,
subcutaneous nodules, and/or clinically reported symptoms of sicca syndrome. Serositis
was diagnosed clinically and/or radiologically. Musculoskeletal disease was defined by
arthritis involving two or more peripheral joints, clinically reported myalgias or arthralgias,
and/or myositis accompanied by elevated muscles enzymes. Neurological disease included
clinical psychosis, peripheral neuropathy, and/or seizures in the absence of drugs or other
known metabolic causes. Vascular disease was defined by clinically reported Raynaud’s,
vasculitis, cutaneous vasculitis, deep venous thrombosis by Doppler ultrasound, and/or
digital or leg ulcerations thought secondary to vascular pathology. Renal disease was
diagnosed histologically, on the basis of persistent proteinuria (>0.5gm/day), and/or
cellular cast(s) on urinalysis. Hematologic disorders were defined by hemolytic anemia
(documented by positive Coombs and/or reticulocytosis), leukopenia (<4,000/mm3),
lymphopenia

(< 1,500/mm3),

and/or

thrombocytopenia

(<100,000/mm3).

Hypocomplementemia and rheumatoid factor positivity were defined according to
individual laboratory guidelines.
Sample size was determined by a nomagram, using the standard difference (SD) of
the samples and a statistical power of 80% ((3 < 0.20). Standard difference was determined
as
Pi -P2
SQRT[pm(l-pm)]

where pi and p2 are the expected proportions of events in the experimental and control
groups, respectively, and pm is the mean of the proportions ((pi + p2)/2). The number of
experimental and control specimens required is equal to half of the resulting sample size
(n).
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The experimental and control specimens were not equivalent in number; therefore, a
correction for power was made. The method of estimating the sample size for a given
power estimation used was:
N = N'(l + k)2
4k

where k = the ratio of experimental specimens to control specimens and N' = the original
sample size (n) required as determined by nomogram.
Given 68 experimental patients and 12 control patients, k = 5.7. The adjusted
sample size is (rearranging the above equation):
N (4) k
(1 + k)2

or 41. By nomagram, this gives a SD of approximately 0.875 for a significance of 95% (a
= 0.05).
By empirically testing pfs, the SD equals 0.84 for a prevalence of 30%. Hence, 80
patients containing 12 control patients supplied enough specimens to determine statistical
significance at 95% confidence and 80% power, as long as the prevalence of the tested
autoantibody or clinical characteristic was 30%. (If 68 negative controls would have been
run, a prevalence of 10% would have been statistically significant.)
Clinical/autoantibody associations were determined using Chi-square analysis with
Yates' correction.

A resulting P-value < 0.05 was considered significant. Clinical

manifestations and antibodies with a frequency > 10% in the study population were
analyzed, however only the tested entities with a frequency of > 30% have a statistical
power of 80%.
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RESULTS

The Study Population

Sixty-eight patients fulfilling the ARA Revised

Criteria for systemic lupus erythematosus were studied (Table 3).
female to male patient ratio was 9:1.

The

The white to black patient ratio was

3:1. The mean age at disease onset was 30.2 +/- 13.9 years. One quarter of
the patients reported a first degree relative as having either rheumatoid
arthritis (RA) or SLE.

The mean duration of disease at the time the sera

samples were drawn was 8.2 years.

The mean duration of disease at the

time of the chart review was 10.9 years.

Clinical Aspects

Initial clinical factors are shown in Table 4.

Possible

precipitating events identified include pregnancy in nine patients and
infection in two patients.

The initial clinical signs/symptoms reported

include, in decreasing order of frequency:
ITP,

fatigue,

serositis,

Raynaud's,

arthralgias, arthritis, rash,

extremity

weakness,

alopecia,

photosensitivity, subcutaneous nodules, myalgias, aseptic meningitis,
cutaneous vasculitis, proteinuria, hemolytic anemia, dyspnea, and chest
pain.

Fourteen patients had greater than or equal to two initial signs or

symptoms.
Cumulative frequencies of the individual clinical manifestations of
SLE in the study population are shown in Table 5. Chi-square analysis with
Yates' correction was used to study associations between autoantibodies
and SLE clinical manifestations.

Those clinical manifestations and

antibodies of > 10% frequency in the study population were considered,
including:

dermatologic

disease

as

a whole

(malar rash,

alopecia,

photosensitivity, mucous membrane ulcers, discoid rash, livedo reticularis,
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sicca syndrome, and/or subcutaneous nodules), malar rash, alopecia,
photosensitivity, mucous membrane ulcers, discoid rash, serositis as a
whole (pleuritis and/or pericarditis), musculoskeletal disease as a whole
(arthritis, arthralgias, myalgias, and/or myositis), arthritis, neurological
manifestations of disease as a whole (psychosis, peripheral neuropathy,
and/or seizures), Raynaud’s, vasculitis, cutaneous vasculitis, history of a
thrombotic event, renal disease as a whole (proteinuria, RBC casts in
urine, and/or renal failure), proteinuria, RBC casts in urine, hematologic
disease

as

a

whole

(leukopenia,

hemolytic

anemia,

and/or

thrombocytopenia), leukopenia, hemolytic anemia, thrombocytopenia,
hypocomplementemia, rheumatoid factor positivity, and corticosteroid
treatment at the time of phlebotomy.
The following entities were not studied because of either a lack of
statistical power of 80% secondary to a frequency less than 10% or a
subjective lack of utility:

livedo reticularis, sicca syndrome, subcutaneous

nodules, pericarditis, myalgias, myositis, seizures, vascular disease as a
whole, digital ulcerations, leg ulcerations, renal failure, lymphopenia,
VDRL false positivity, headache, and thyroiditis.
The associations found are shown in Table 5. A P value < 0.05 for a
confidence level > 95% was considered statistically significant.
findings by autoantibody follow.

Notable

Anti-dsDNA antibodies were associated

with serositis, pleuritis ((3 > 0.20), musculoskeletal disease manifestations,
arthritis, renal disease, and hypocomplementemia.

No association

between dsDNA antibodies and CNS disease was found.
antibodies

were associated with

discoid rash

((3

Anti-histone

> 0.20), serositis,

musculoskeletal disease manifestations, leukopenia, thrombocytopenia ((3 >
0.20), and hypocomplementemia. Anti-Sm antibodies were associated with
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serositis and pleuritis (|3 > 0.20). No association between race and Sm was
shown ((3 > 0.20).

Anti-Ul RNP antibodies correlated with cutaneous

disease, serositis, and pleuritis ((3 > 0.20).

Anti-Ro antibodies were

associated with neurological disease and hemolytic anemia.

No correlation

between anti-Ro antibodies and RF positivity was found. Anti-La antibodies
were associated with RF positivity.
Forty-three

percent

of the

study

population

were

receiving

corticosteroid treatment at the time of phlebotomy. Corticosteroid treatment
correlated with autoantibodies to histones, dsDNA and/or Ro.
Inter-autoantibody associations were studied (Table 6).

Anti-histone

antibodies associated with anti-dsDNA antibodies, anti-Ul RNP antibodies,
and weakly with anti-Ro antibodies.

Anti-dsDNA antibodies were also

associated with anti-Ul RNP antibodies and anti-Sm antibodies.

Notably,

anti-Sm antibodies did not statistically correlate with anti-Ul RNP
antibodies, however, the chi-squared analysis is not statistically significant
at an Sm frequency of 14.7%. The study did show that 6 of 10 Sm positive
patients had the U1 RNP specificity as well. Anti-Ro and anti-La antibodies
were statistically associated.

Autoantibodies
ELISA

and

specificities:

Sera of the 68 SLE patients and 12 controls were studied by

immunoprecipitation

for

the

following

autoantibody

dsDNA, histone, Sm, U1 RNP, Ro, La, rRNP, PCNA, Ku, Ki,

and other autoantibodies (unidentified band(s) by immunoprecipitation).
The following autoantibody sets were considered:

dsDNA and/or histone,

Sm and/or U1 RNP, Ro and/or La, rRNP, PCNA, Ku, Ki, and other
(unidentified

protein bands

on

SDS

polyacrylamide gels

after 35S
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immunoprecipitation).

The results by patient number and frequency

percent are shown in Tables 7 and 8.
Autoantibody frequency (%) results by ELISA include:

anti-dsDNA

39.7%, anti-histone 51.5%, anti-Sm 14.7%, anti-Ul 33.8%, anti-Ro 39.7%,
and anti-La 14.7%.

Autoantibody set results by ELISA include:

anti-

dsDNA and/or anti-histone 58.8%, anti-Sm and/or anti-Ul RNP 39.7%, and
anti-Ro and/or anti La 41.2%.
Using 35S

immunoprecipitation,

frequency percent

resulted:

the

following

specificities

anti-Ro 42.6% and anti-La 19.1%.

autoantibody set, the following frequencies were found:
anti-Ul RNP 39.7%, and anti-Ro and/or anti-La 44.1%.

in
By

anti-Sm and/or
Protein bands on

SDS polyacrylamide gels similar to those found in prototypic sera with
specificities for ribosomal proteins, Ku, and Ki were found in the following
percentages, respectively: 4.4%, 4.4%, and 2.9%.

These frequencies are not

sufficiently high for significant statistical analysis as stated previously.
Fourteen (20.5%) patients had protein bands of unidentified specificities.
Eleven patients (16%) were autoantibody negative by both ELISA and
immunoprecipitation.

All positive control plasma samples were positive

for respective specificities by ELISA. All negative control plasma and sera
were autoantibody negative by ELISA.

By immunoprecipitation, no

negative control sera had autoantibodies to Sm/Ul RNP, Ro, La, rRNP,
PCNA, Ku or Ki.

Three normal control sera had protein bands of

unidentified specificity.
The average number of antibodies and antibody sets per patient were
determined as 2.34-2.37 and 1.72-1.74, respectively (Table 9).

Considering

only antibody positive patients, the average number of antibodies and
antibody sets per patient were 2.79-2.82 and 2.01-2.07, respectively.

The
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distributions of the number of antibodies and antibody sets per patient are
shown in Figures 4 and 5.

Using ELISA and immunoprecipitation results:

twelve patients each had one, two, or three autoantibodies; thirteen patients
had four antibodies; five patients showed five antibodies; and two patients
had six antibodies. By antibody set: 17 patients had one set, 19 patients had
two sets, 14 patients had three sets, and five patients had four autoantibody
sets. (Table 8)
The number of autoantibody sets by duration of disease at the time of
phlebotomy was plotted (Figure 6). No correlation was shown.
Autoantibody profiles found in the literature are shown in Table 8.
Data sets were analyzed for the minimal possible number of reported
antibody sets per patient (Table 10). Twelve studies found at least greater
than than one set per patient, three studies found at least greater than two
sets per patient, and one study found at least greater than three sets per
patient.
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Table 3
Characteristics of the study group.

Total number of patients = 68
61
(90%)
Female
Sex
7
(10%)
Male
(62%)
42
White
Race
(22%)
Black
15
1
(1.5%)
Hispanic
10
(15%)
Unknown
Mean age at disease onset (years) = 30.2 SD +/- 13.9
Median age at disease onset (years) = 29.0
Mean duration of disease at time of phlebotomy (years) = 8.2
Mean duration of disease at time of chart review (years) = 10.9
Positive family history = 18 (26%)
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Table 4
Initial Clinical Factors.

Possible precipitating event
Pregnancy
Infection
First clinical sign/symptom
arthralgias
arthritis
rash
ITP
fatigue
serositis
Raynaud's
extremity weakness
alopecia
photosensitivity
subcutaneous nodules
myalgias
aseptic meningitis
cutaneous vasculitis
proteinuria
anemia
dyspnea
chest pain

Number of patients
9
2
19
13
6
4
4
3
3
2
1
1
1
1
1
1
1
1
1
1

(1 discoid)

Patients reporting > 2 initial signs/symptoms = 14
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Table 5
Clinical profile ofSLE patient population.
Disease manifestation

No. with
diagnosis

Frequency
of occurrence (%)

55
34
28
27

81%
50
41
40

19
8
4
2

28
12
6
3

2
24

3
35

18

27

pericarditis*1
Musculoskeletal

6
57

9
84

arthritis
arthralgias1
myalgias*1
myositis*1
Neurological manifestations
psychosis*
peripheral neuro*
seizures*1
Vascular1
Raynaud's
vasculitis
cutaneous vasculitis*
thrombotic event*
digital ulcerations*1
leg ulcerations*1
Renal
proteinuria
RBC casts in urine
renal failure*1

48
27
6
3
22
12
7
2
35
21
21
16
7
6
1
30
27
22
6

71
40
9
4
32
18
10
3
52
31
31
24
10
9
2
44
40
32
9

Cutaneous
malar rash
alopecia
photosensitivity
mucous membrane
ulcers*
discoid rash*
livedo reticularis*1
sicca syndrome **
subcutaneous
nodules *'
Serositis

pleuritis*

Antibody association

P

U1 RNP

<.05

His

<.05

dsDNA
Sm
U1 RNP
His
dsDNA
U1 RNP
Sm

<.01
<.01
<.05
<.05
<.01
<.05
<.05

His
dsDNA
dsDNA

<.05
<.05
<.05

Ro

<.02

dsDNA

<.05
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Table 5 (continued)

Disease manifestation

No. with
diagnosis

43
25
leukopenia <4K
20
hemolytic anemia*
thrombocytopenia *
12
(<100K)
4
lymphopenia *1
(<1.5K)
40
Constitution symptoms'
34
fatigue1
21
fever1
8
wt loss (>5 lb.)*1
Other
Hypocomplementemia
Heme1

low C31
low C41
Rheumatoid Factor *
(out of 22 patients)
VDRL false "+" *'
(out of 17 patients)
HA*1
thyroiditis *'
Corticosteroid Tx

*

(3

>

Frequency
of occurrence (%)
63%
37
30
18

His
Ro
His

<.05
<.02
<.05

dsDNA
His

<.01
<.02

La

<.01

His
dsDNA
Ro

<.01
<.01
<.05

59
50
31
12

67
63
41

5

29

8
5
29

12
7
43

0.20

P

6

32
30
9

'not tested for autoantibody correlation

Antibody association
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Table 6
Inter-autoantibody Associations.

Antibody
Histone

dsDNA

Sm
U1 RNP

Ro
La
*p >0.20

Associated Antibody

Chi-Squared

dsDNA
U1 RNP
Ro
Histone
U1 RNP
Sm
dsDNA
U1 RNP
Histone
dsDNA
Sm
La
Histone
Ro

19.0
13.6
3.86
as above
6.58
4.37
as above
2.92*
as above
as above
as above
3.86
as above
as above

P
<.001
<.001
<.05
<.02
<.05
<.l

<.05
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Table 7
Autoantibody profiles (Part I).

Specificity

No. of pts with specificity
ELISA
IPP

27
dsDNA
35
Histone
dsDNA/Histone set
40
10
Sm*
23
U1 RNP
27
Sm/Ul RNP set
27
Ro
10
La*
28
Ro/La set
?rRNP*
?PCNA*
?Ku*
?Ki*
?Other
High Band (HB) A 170 kD
HBB 125 kD
HB C 100 kD
HB D 98 kD
HB E 97 kD
HB F 78 kD
HB G 75 kD
HB I 70 kD
Low Band (LB) A 43 kD
LB B 35 kD
LB C 17 kD
Three bands
p > 0.20

27
29
13
30
3
0
3
2
14
3
1
1
1
1
1
1
1
1
1
1
1

Frequency (%)
ELISA
IPP
40%
52
59
15
34
40
40
15
41

40%
43
19
44
4
0
4
3
21
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Table 8
Autoantibody profiles (Part II).

Number of antibodies
or set(s)

Number of patients
ELISA
1PP

Frequency (%) of pts
ELISA
IPP

1 antibody
2 antibodies
3 antibodies
4 antibodies
5 antibodies
6 antibodies
1 antibody set
2 antibody sets
3 antibody sets
4 antibody sets
Autoantibody neg. patients*

14
11
13
11
5
2
18
20
13
5
11

21%
16
19
16
7
3
27
29
19
7
16

12
12
12
13
5
2
17
19
14
5
11

18%
18
18
19
7
3
25
28
21
7
16

*p > 0.20

Table 9
Autoantibodies or antibody sets per patient.

ELISA
Average
Average
Average
Average
P >0.20

number of antibodies/ patient
2.34
number of antibodies/autoantibody positive patient 2.79
number of antibody sets/patient
1.72
number of antibody sets/autoantibody positive pt. 2.05

IPP
2.37
2.82
1.74
2.07
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Table 10
Autoantibody profiles in the literature.

Author

Autoantibody Frequency (%)
dsDNA

This study
68 pts
Arnett (1988)2’3-4
60 Black pts
106 White pts
Bell and Maddison (1980)5
64 White pts
Bernstein et al. (1984)4
270 pts
Boey et al. (1988)6
94 Asian pts
9 psych pts
Bonfa and Elkon (1986)4 7
i-RNP “+” pts
18 psych pts
14 nonpsych pts
Hamilton et al. (1988)2 3-4
106 White pts
Hochberg (1985)8 9
150 pts
113 White pts
37 Black pts
Jayaram (1990)4-8
30 Indian pts
Juby (1991 )2 9
108 Canadian pts
Kiparski (1990)4
(rev in Swaak et al.)
Maddison et al. (1985)2-3
63 UK pts
Notman (1975)1
50 pts
Scopelitis et al.(1980)iau
73 Black pts
Speransky (1988)4-10
107 USSR pts
Swaak (1990)4'10’12
164 Netherlands
Westgeest (1990)4
(rev in Swaak et al.)

Antibody sets/pt

His

Sm

U1RNP Sm/Ul Ro

La

52

15

34

40

40-43

15-20

25
10

40
23

52
26

58
45

20
20

22

25

2.5

25'

1.72
40

>1.1

>1.08
61

43
88

81
100

44
50

27
30

7

23

24

8

26
77

32
66

63

12

>2.09
>3.64

33
36

33
36

50
36

11
0

>2.27
>2.22

10

23

15
24

32
41

26

45-37 21-11

33
30

12
11

30

73

27

63

22

1

21

36

17

7

10

20

37

14

33-55

15-24

17-33 30-46
70

52

28

26

32

40

29

0

>1.8
>1.95
>1.36

>1.43
74

>1.31
54

21

27

50

48

76

9-22

9-29

12-28

18-45

8-29

8-14

10-16

>1.03
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Table 10 (continued)

Author

Autoantibody Frequency (%)
dsDNA

Williams (1990)2 * 4 *
(rev in Swaak et al.)
Williamson et al.(1983)6 * * * * 11
71 US pts

2elisa
-^immunodiffusion
4counterimniunoelectrophoresis
-'radioimmunoassay and precipitin analysis
^immunoprecipitation
2 western blot
^Crithidia
^double diffusion
'^Farr
11 FAN A

' 2Peg

His

Antibody sets/pt

Sm

U1RNP

19

25

47

5

32

37

30

11

Sm/Ul Ro

La
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Figure 1

snRNP

Figure 1. 35S Immunoprecipitation of standard sera of the following
specificities by lane: MW marker, Ro, La, PCNA, Ki, Sm, Ku, and
normal control.
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Figure 2
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Figure 2. 35S Xmmunoprecipitation of ribosomal control sera (lanes
2-7) with MW standard in lane 1 and normal control sera in lane 8.
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Figure 3

Figure 3. Sample 35S Immunoprecipitation of study population sera
showing: MW standard, Sm, Sm, no autoantibodies, no
autoantibodies, Ki, and normal control sera.
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Figure 4
Distribution of the number of autoantibodies per patient.

Figure 4. Sera of 68 patients fulfilling the 1982 Revised Criteria for the
Classification of Systemic Lupus Erythematosus were assayed by 35S
immunoprecipitation and ELISA for autoantibodies (dsDNA, histone, Ro, La,
Sm, U1 RNP, rRNP, PCNA, Ku, Ki, and/or other) and the number of
autoantibodies in each patient serum was calculated. The distribution of the
number of patients with each respective number of autoantibodies is shown.
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Figure 5

of Patients

Distribution of the number of autoantibody sets per patient.

Figure 5. Sera of 68 patients fulfilling the 1982 Revised Criteria for the
Classification of Systemic Lupus Erythematosus were assayed by 35S
immunoprecipitation and ELISA for autoantibody sets (dsDNA/histone, Ro/La,
Sm/Ul RNP, rRNP, PCNA, Ku, Ki, and/or other) and the number of
autoantibody sets in each patient serum was calculated. The distribution of the
number of patients with each respective number of autoantibody sets is shown.
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Figure 6
Number of autoantibody sets by duration of disease at phlebotomy.

Figure 6. Sera of 68 patients fulfilling the 1982 Revised Criteria for the
Classification of Systemic Lupus Erythematosus were assayed by 35S
immunoprecipitation and ELISA for autoantibody sets (dsDNA/histone, Ro/La,
Sm/Ul RNP, rRNP, PCNA, Ku, Ki, and/or other). The duration of disease at
time of phlebotomy for each patient was determined by chart review. Each
patient is plotted, showing the number of autoantibody sets versus the duration
of disease.
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DISCUSSION

Using both 35S immunoprecipitation and ELISAs, the autoantibody
profiles of 68 patients fulfilling the ARA Revised Criteria for systemic lupus
erythematosus were determined. Additionally, autoantibody profiles of SLE
patients previously reported in the literature were reviewed and analyzed.
The clinical manifestations of disease in the study population were collected
through clinical chart review, and Chi-square analysis was used to study
possible associations between individual autoantibodies, and between
autoantibodies and clinical manifestations.
The prevalence of antibodies to dsDNA (40%), histones (52%), Sm
(15%), U1 RNP (34%), Ro (40-43%), and La (15-19%), found using both 35S
immunoprecipitation and ELISA, in this previously unreported population
are consistent with the literature (Table 1).

This confirms that a high

uniformity of antibody specificities exists between different populations.
Associations

between

clinical

disease

manifestations

and

autoantibody specificities previously reported in the literature and
confirmed in this study include the following:
renal pathology;

anti-dsDNA antibodies and

anti-dsDNA and hypocomplementemia; and anti-Ul

antibodies and serositis. Associations previously reported in the literature
which were not found in this study include the following:

anti-dsDNA

antibodies and neurologic disease, malar rash, or hemolytic disease; anti¬
histone antibodies and photosensitivity; anti-Ro antibodies and rheumatoid
factor positivity, vasculitis, or thrombocytopenia;

anti-La antibodies and

CNS disease, or protection against renal disease; anti-Ul RNP antibodies
and vasculitis; and anti-Sm antibodies were not protective against CNS or
renal diseases.

Interestingly,

anti-La antibodies, not anti-Ro antibodies,
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correlated with RF positivity which, if the particle hypothesis is true, would
support an association between the Ro/La set and RF positivity. Also, anti¬
histone antibodies, as well as anti-dsDNA antibodies, correlated with
hypocomplementemia. Interestingly, anti-Ro antibodies were the only
antibodies associated with CNS manifestations of disease.
Additionally, the more prevalent autoantibodies correlated with the
more prevalent clinical manifestations, anti-dsDNA antibodies correlated
with musculoskeletal

disease

and

serositis,

anti-histone

antibodies

correlated with many clinical manifestations (hemolytic disease, serositis,
and musculoskeletal disease), and anti-Ro antibodies correlated with
hemolytic disease.
disease

Because of the high prevalence of these antibodies and

manifestations,

these

associations

may

be

coincidental.

Corticosteroid treatment correlated with anti-dsDNA, anti-histone, and
anti-Ro antibodies (the three most prevalent antibodies), indirectly
suggesting that patients with these particular antibodies, or patients with
higher numbers of antibodies, may have more severe disease.
The role of specific autoantibodies in the pathogenesis of the clinical
manifestations has long been hypothesized.

The present study did not

directly address the role of autoantibodies in the pathogenesis of SLE.
However, in the present study, anti-dsDNA antibodies correlated with
hypocomplementemia and renal pathology which is consistent with a role
of dsDNA in the pathogenesis of lupus renal disease. (As stated previously,
it is generally believed that anti-dsDNA antibodies form immune complexes
which lead to renal injury.)

This study did not address a correlation

between anti-Ro antibodies and neonatal lupus or subacute cutaneous
lupus.

56

Confirmed in this study are previously reported autoantibody set
patterns of the autoimmune response: Ro with La, and dsDNA with histone
(all anti-La sera, except one serum, contained anti-Ro, and, of 27 dsDNA
positive sera, 22 sera also had anti-histone specificity). Although secondary
to the sample size, the study was not able to statistically comment on an
association between Sm and U1 RNP,
both Sm and U1 RNP.

six of ten Sm positive patients had

Chi-square analysis most strongly correlated anti¬

histone and anti-dsDNA antibodies. Anti-histone antibodies also correlated
with anti-Ul RNP and anti-Ro antibodies.

(Given an average number of

three autoantibodies per patient and that these specificities are the most
prevalent autoantibody specificities, this association can be explained by
statistical probability.)

Chi-square analysis also correlated anti-Ro with

anti-La antibodies, a commonly found set.
The present study defined more clearly the average number of
autoantibody sets per lupus patient than the studies currently in the
literature.

The current study and 12 identified studies in the literature

showed an average of greater than one autoantibody set per patient.
Furthermore, it has been shown that severely ill SLE patients can have
greater than six autoantibody specificities (Boey et al., 1988). Although this
study did not examine disease severity, two patients had six autoantibody
specificities. The greatest number of antibody sets found in a single patient
was four, which was shown in five patients.
This study supports some theories of etiology over others.

At least

nine different specificities were demonstrated in this group of SLE patients
supporting the generally accepted notion that SLE is manifested by a
polyclonal autoantibody response.

Secondly, autoantibodies to epitopes on

the same macromolecular structure, such as Ro and La, Sm and Ul, and
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dsDNA and histones, tended to occur in linked sets further supporting that
macromolecular structures are targeted in the immune response of SLE.
Other research also supports this concept.

It has been shown that histone-

specific T cells can help anti-dsDNA antibody production. In MRL/lpr mice,
antibodies specific for native chromatin are detected before DNA and
histone specificities.

Craft et al. have shown in normal mice that once T

cell tolerance to one snRNP protein is lost, in the presence of spliceosomes,
the immune response can expand to target other snRNP proteins.

(Craft

1992)
On an average, approximately two sets were found in each patient.
These results support a global defect in immune tolerance; therefore, the
following etiologic theories appear more likely: (1) polyclonal T cell
activation (2) polyclonal B cell activation (3) suppressor T cell defect (4) Th
overactivation (5) role of immunological

privileged sites (6) activation of

ignorant cells (7) defect in T cell tolerance or (8) defect in B cell tolerance.
However, the limited number of autoantibody specificities in the present
study suggests that an antigen-directed mechanism is also functioning.
This suggests that the etiologic defect is not simply a pure polyclonal T cell
activation defect, polyclonal B cell activation defect, defect in T suppressor
or T helper cells, or defect in T or B cell tolerance.

Other evidence

supporting immunogen-directed B cell autoantibody production is outlined
by Craft (unpublished), "autoantibodies in lupus are high affinity, high
titer, and of IgG isotype.

In lupus mice, polyclonal B cell activation

precedes specific ANA production."

He suggests that autoantibody

production may be divided into two steps: polyclonal B cell activation and
then clonal selection by self antigens.
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The results of this study are not as consistent with the etiologic
theories which imply that the autoimmune response is due solely to an
antigenically similar cross-reacting antigen, which include the theories of
molecular mimicry, cryptic self, and neoself.

In order for this data to be

consistent with the molecular mimicry model, all antigens targeted by an
individuals sera would at some point need to be a part of the same
macromolecular structure; more than one molecular mimicry event on
average must occur; or the inciting antigen must not be protein specific but
charge specific.
The present study has limitations. The study sample size of 68 SLE
patients was not adequate to study the prevalence of anti-ribosome P,
PCNA, Ku, or Ki antibodies, as well as various clinical manifestations,
with statistical significance.
patterns,

This study did not correlate autoantibody

only specific autoantibodies, with clinical manifestations.

Furthermore, the utility of studying antibody/clinical manifestations has
been questioned (Tan 1989; Craft 1992), and it is important to remember that
normal individuals have been shown to possess low levels of antibodies to
Ro (15%), La (7.5%), dsDNA, and ssDNA.
The methods used have limitations. Although the prevalence of antiribosomal P proteins has been studied with immunoprecipitation in the
past (Boey et al., 1988), western blotting is a more specific technique (Elkon
et al., 1988).

35S immunoprecipitation labels only those proteins with

methionine; therefore, methionine deficient proteins were not adequately
detected with the 35S immunoprecipitation method (although U1 RNP, Sm
Ro, and La were also detected using ELISAs which are sensitive regardless
of methionine content).

The utility of Chi-square analysis in the medical

literature has been questioned (Jekel, personal communication).
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Finally, disease activity and therapy may influence autoantibody
levels (Houtman et al., 1985).

Forty-three percent of patients in this study

were on steroids or anti-nuclear therapy when sera were drawn; active
lupus was not a selection criterion for sera used.

Therefore, frequencies in

this series may not be strictly comparable to other studies in the literature.
The utility of studying autoantibody profiles in SLE patients is
multifold.

For example, using human autoantibodies, the molecular

structure of many autoantigens and cellular processes such as pre-mRNA
splicing and DNA replication have been elucidated.

Autoantibody profiles

have etiologic, diagnostic, and therapeutic utility. The results of this study
and studies found in the literature support specific etiologic theories.

This

study confirmed that several autoantibody specificities can be used to
predict

particular

clinical

manifestations.

Furthermore,

autoantibodies has also led to many therapeutic strategies.

studying

For example,

extended survival in NZW/NZB mice, a murine model of lupus, by the
administration of an anti-idiotypic antibody has been demonstrated by
Hahn and Ebling (reviewed in Christian and Elkon, 1986).

FURTHER RESEARCH

At least two specific questions arose during the course of this project.
First, twenty patients had previously unidentified bands which were
considered individual specificities.

This may be valid given that it is very

possible that these represent previously unidentified specificities. However,
it is also possible that these bands represent a degradation product;
therefore, leading to a slight overestimation of the number of autoantibody
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sets per patient. (The average number of sets, disregarding these bands, is
still greater than one.)
Secondly, sixteen patients had no specificities identified.
several

possible explanations:

(1) these

patients

do

There are

not have

any

autoantibodies yet have SLE; (2) these patients do not have either
autoantibodies or SLE; (3) the assays used in this study are not adequate to
detect the specificities in these sera; or (4) the autoantibodies were degraded
while in storage.
These issues represent opportunities of further research and, as
newer assays are developed, other investigators may want to re-screen
these sera. More globally, this project serves as a reminder that the etiology
of SLE is a complex question which has only begun to be answered.
Nevertheless, all scientific questions must be answered in parts, and much
light-shedding data has been accumulated.

This project suggests that

further research may best focus on hypotheses that account for a global
defect in tolerance.
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